189 related articles for article (PubMed ID: 30229578)
1. Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease.
Choi DH; Jung CH; Mok JO; Kim CH; Kang SK; Kim BY
Endocrinol Metab (Seoul); 2018 Sep; 33(3):387-394. PubMed ID: 30229578
[TBL] [Abstract][Full Text] [Related]
2. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study.
Tobita H; Yazaki T; Kataoka M; Kotani S; Oka A; Mishiro T; Oshima N; Kawashima K; Ishimura N; Naora K; Sato S; Ishihara S
J Clin Biochem Nutr; 2021 Mar; 68(2):173-180. PubMed ID: 33879970
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Euh W; Lim S; Kim JW
Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
[TBL] [Abstract][Full Text] [Related]
4. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
[TBL] [Abstract][Full Text] [Related]
5. Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study).
Ishii H; Nakajima H; Kamei N; Niiya T; Hiyoshi T; Hiramori Y; Ohtsu S; Noto T; Shimono D
Diabetes Ther; 2020 Dec; 11(12):2959-2977. PubMed ID: 33057967
[TBL] [Abstract][Full Text] [Related]
6. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
Hepatol Res; 2017 Sep; 47(10):1072-1078. PubMed ID: 27925353
[TBL] [Abstract][Full Text] [Related]
7. Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice.
Zhao DM; Li CQ; Sun YM; Fan JY; Wu N; Sun YN; Sun XY
Endokrynol Pol; 2023; 74(2):190-196. PubMed ID: 37039492
[TBL] [Abstract][Full Text] [Related]
8. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.
Tobita H; Sato S; Miyake T; Ishihara S; Kinoshita Y
Curr Ther Res Clin Exp; 2017; 87():13-19. PubMed ID: 28912902
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
Guo M; Xi G; Yang N; Yao H
Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
[TBL] [Abstract][Full Text] [Related]
10. Modifiable clinical and lifestyle factors are associated with elevated alanine aminotransferase levels in newly diagnosed type 2 diabetes patients: results from the nationwide DD2 study.
Mor A; Svensson E; Rungby J; Ulrichsen SP; Berencsi K; Nielsen JS; Stidsen JV; Friborg S; Brandslund I; Christiansen JS; Beck-Nielsen H; Sørensen HT; Thomsen RW
Diabetes Metab Res Rev; 2014 Nov; 30(8):707-15. PubMed ID: 24639417
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus.
Cho HA; Jung YL; Lee YH; Lee YC; Lee JE; Lee SJ; Jeong SJ; Kim CH
J Obes Metab Syndr; 2017 Jun; 26(2):107-113. PubMed ID: 31089504
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study.
Lee PCH; Gu Y; Yeung MY; Fong CHY; Woo YC; Chow WS; Tan K; Lam KSL
Diabetes Ther; 2018 Feb; 9(1):285-295. PubMed ID: 29322486
[TBL] [Abstract][Full Text] [Related]
13. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
14. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.
Arai T; Atsukawa M; Tsubota A; Mikami S; Ono H; Kawano T; Yoshida Y; Tanabe T; Okubo T; Hayama K; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kaneko K; Emoto N; Nagao M; Inagaki K; Fukuda I; Sugihara H; Iwakiri K
Ther Adv Endocrinol Metab; 2021; 12():20420188211000243. PubMed ID: 33815743
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review.
Dwinata M; Putera DD; Hasan I; Raharjo M
Clin Exp Hepatol; 2020 Dec; 6(4):339-346. PubMed ID: 33511282
[TBL] [Abstract][Full Text] [Related]
16. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.
Li WD; Fu KF; Li GM; Lian YS; Ren AM; Chen YJ; Xia JR
World J Gastroenterol; 2015 Aug; 21(32):9607-13. PubMed ID: 26327768
[TBL] [Abstract][Full Text] [Related]
17. [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes].
Huang Y; Fu JF; Shi HB; Liu LR
Zhonghua Er Ke Za Zhi; 2011 Feb; 49(2):139-45. PubMed ID: 21426695
[TBL] [Abstract][Full Text] [Related]
18. Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor.
Sugiyama S; Jinnouchi H; Hieshima K; Kurinami N; Jinnouchi K
Cureus; 2020 Feb; 12(2):e7110. PubMed ID: 32175210
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
[TBL] [Abstract][Full Text] [Related]
20. Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.
Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Tanaka M; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
J Clin Med Res; 2018 Jun; 10(6):466-477. PubMed ID: 29707088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
